CMC Biologics has inked an agreement with biotech start-up OncoSynergy to develop cell lines and for process development, analytical development, and manufacturing of both non-GMP material for early toxicology testing and cGMP material for IND-enabling toxicology studies and Phase I clinical trials. This work, the firms say, will advance OncoSynergy’s OS2966 mAb program.
OS2966, according to OncoSynergy, can block a major path for growth and therapy resistance in cancer; it is currently being developed for the treatment of glioblastoma. The OS2966 program is based on the firm’s “targeted synergy” approach, a strategy that reportedly allows broad inhibition of multiple cancer growth mechanisms with a single drug. CMC Biologics will execute this project at its Copenhagen development and manufacturing facility, while OncoSynergy EU will lead the project in France.
OncoSynergy isn’t the only firm CMC Biologics has been working with this year: In May, it entered an agreement with RuiYi to use its CHEF1® high-productivity expression plasmid to accelerate development of a cell line for RuiYi’s monoclonal antibody RYI-008.